Clinical trials: Clinical Trial, Phase I
Advanced Solid Cancer
Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer
The trial is divided into three periods. Dosing will be the first day of each cycle, 21 days per cycle. The first period is the day of first study drug delivery until the 21st day, that is, the first treatment cycle.
- Trial name
- NCT03884517
- Testing
- BAT8003
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Bio-Thera Solutions
Healthy
PAC-14028 in Healthy Male Volunteers
1. Primary Objective: To evaluate safety and tolerability of single and multiple oral dosing of PAC-14028 in healthy male volunteers. 2.
- Trial name
- NCT01264224
- Testing
- PAC-14028
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Amorepacific Corporation
Colorectal Neoplasms, Hepatocellular Carcinoma
Dendritic Killer Cell-based Immunotherapy for Solid Tumors
The primary objective of this study is to evaluate the safety of autologous dendritic killer cell (DKC) in patients with metastatic solid tumor and to evaluate the maximum tolerated dose (MTD) of DKC.
- Conditions
- Colorectal Neoplasms, Hepatocellular Carcinoma, Neoplasm Metastasis
- Trial name
- NCT02882659
- Testing
- Dendritic Killer Cell (DKC)
- Volunteers
- 18 people
- Sponsor
- FullHope Biomedical Co., Ltd.
Heart Failure, Congestive
A Phase I/II Clinical Study of SK&F-105517-D in Japanese Patients With Chronic Heart Failure
The primary objective of this study is to evaluate the safety and tolerability of SK\&F-105517-D in japanese patients with chronic heart failure.
- Trial name
- NCT00742508
- Testing
- SK&F-105517-D 10 mg capsule, Carvedilol-immediate release (IR) 2.5 mg tablet, SK&F-105517-D 20 mg capsule
- Where
- 23 sites in Japan
- Volunteers
- 41 people
- Sponsor
- GlaxoSmithKline
Advanced Malignant Solid Tumor
To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors
This is a Phase I open, multi-center, first-in-human study evaluating JSKN016 in subjects with advanced metastatic solid tumors, divided into dose escalation and dose extension.
- Trial name
- NCT06592417
- Testing
- JSKN016 injection
- Where
- 2 sites in China
- Volunteers
- 140 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Healthy Volunteers
Phase I Study to Evaluate the Safety of Dexibuprofen 200mg Under Fasting and Fed Conditions
Phase I Study to Evaluate the Safety of Dexibuprofen 200mg (Apsen Pharmaceuticals A / S.) After a Single and Multiple Dose Oral Administration in Healthy Participants of Both Sexes Under Fasting and Fed Conditions.
- Trial name
- NCT02956525
- Testing
- Dexibuprofen
- Where
- Brazil
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Apsen Farmaceutica S.A.
Healthy Volunteers
Phase 1 Clinical Study of MWX203 Injection in Healthy Subjects
This is a randomized, double-blind, placebo-controlled, single ascending dose Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of MWX203 Injection in healthy…
- Trial name
- NCT07799025
- Testing
- MWX203 S1, MWX203 S2, MWX203 S3
- Where
- China
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Pancreatic Adenocarcinoma, Ovarian Cancer
Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
This Phase I/II trial evaluates LOAd703 in patients with cancer (pancreatic, biliary, colorectal or ovarian) together with their standard of care chemotherapy or using gemcitabine immune-conditioning.
- Conditions
- Pancreatic Adenocarcinoma, Ovarian Cancer, Biliary Carcinoma, Colorectal Cancer
- Trial name
- NCT03225989
- Testing
- LOAd703
- Where
- 2 sites in Sweden
- Volunteers
- 47 people
- Sponsor
- Lokon Pharma AB
Healthy Subjects
Evaluation of Pharmacokinetic and Safety of NVP-1705 and NVP-1705-R in Healthy Subjects
The purpose of this study is to compare the pharmacokinetics and safety of NVP-1705 and NVP-1705-R.
- Trial name
- NCT05141110
- Testing
- NVP-1705, NVP-1705-R
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- NVP Healthcare
Healthy Male Volunteers
Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects
Part I of the study： This is a randomised, single-dose, subcutaneous injection, parallel study designed to compare the PK of HLX14 and EU-sourced Prolia® in healthy Chinese adult male subjects, and to assess the safety…
- Trial name
- NCT04534582
- Testing
- HLX14, EU-Prolia®, US-Prolia®
- Where
- China
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
POMES Syndrome, Relapsed and Refractory POMES Syndrome
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES
The goal of this clinical trial is to study the feasibility and efficacy of anti-CD19/BCMA bispecific chimeric antigen receptors (CARs) T cell therapy for relapsed and refractory POMES Syndrome.
- Trial name
- NCT03879382
- Testing
- anti-CD19/BCMA CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Hepatocellular Carcinoma
Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma
The purpose of this study is: Phase1: To evaluate the safety and determine the recommended dose (RD) Phase2: To evaluate the efficacy
- Trial name
- NCT01406574
- Testing
- OPB-31121, OPB-31121 phase2
- Where
- 2 sites in Japan
- Volunteers
- 23 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
This is a Phase I, multicenter, open-label, dose-escalation study of DCDT2980S administered by intravenous (IV) infusion to patients with relapsed or refractory hematologic malignancies.
- Trial name
- NCT01209130
- Testing
- DCDT2980S, rituximab
- Where
- 9 sites in United States
- Volunteers
- 91 people
- Sponsor
- Genentech, Inc.
Osteoarthritis, Rheumatoid Arthritis
A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809
Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover study
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Back Pain, Acute Upper Respiratory Tract Infection
- Trial name
- NCT05214677
- Testing
- DW1809, DW1809-1
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Neoplasms
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent…
- Trial name
- Meteor 1 (NCT02783300)
- Testing
- GSK3326595, Pembrolizumab
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 297 people
- Sponsor
- GlaxoSmithKline
Chronic Kidney Disease(CKD)
A Study to Evaluate the Safety, Tolerability and PK of SK-08
The trial is conducted in a single-center, randomized, double-blind, placebo-controlled, dose-increasing design. To evaluate the safety, tolerability, pharmacokinetics(PK) ,and pharmacodynamics (PD) characteristics of SK-08 in…
- Trial name
- SK-08 (NCT07021157)
- Testing
- SK-08
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Consun Pharmaceutical Group
Pneumococcal Infectious Disease
Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older
Phase I clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Shanghai Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older .
- Trial name
- NCT06678607
- Testing
- Reinovax PCV24 formulation 1, Reinovax PCV24 formulation 2, PPSV23
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Reinovax Biologics Co., LTD
Healthy
Single Dose Phase I Study of FYU-981
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of FYU-981 administered orally to healthy male adults in fasted and fed conditions.
- Trial name
- NCT02348307
- Testing
- FYU-981, (Oral single dosing)
- Where
- Japan
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Fuji Yakuhin Co., Ltd.
Healthy
Pharmacokinetic Profiles of Metformin With DW1029M
Phase I clinical study to evaluate DW1029M influence the pharmacokinetic profiles of Metformin after oral administration in healthy male volunteer
- Trial name
- PMD (NCT02212756)
- Testing
- DW1029M 1200mg and Metformin 1000mg, Metformin 1000mg
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Acute GvHD
Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)
The purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to respond to glucocorticosteroids, for further…
- Trial name
- ALD518-010 (NCT01530256)
- Testing
- ALD518
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- CSL Behring
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.